These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 18393399)

  • 1. De novo design of nonpeptidic compounds targeting the interactions between interferon-alpha and its cognate cell surface receptor.
    Bello AM; Bende T; Wei L; Wang X; Majchrzak-Kita B; Fish EN; Kotra LP
    J Med Chem; 2008 May; 51(9):2734-43. PubMed ID: 18393399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Small molecule mimetics of an interferon-α receptor interacting domain.
    Bello AM; Wei L; Majchrzak-Kita B; Salum N; Purohit MK; Fish EN; Kotra LP
    Bioorg Med Chem; 2014 Feb; 22(3):978-85. PubMed ID: 24433965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutation of the IFNAR-1 receptor binding site of human IFN-alpha2 generates type I IFN competitive antagonists.
    Pan M; Kalie E; Scaglione BJ; Raveche ES; Schreiber G; Langer JA
    Biochemistry; 2008 Nov; 47(46):12018-27. PubMed ID: 18937499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Virus Multiplicity of Infection Affects Type I Interferon Subtype Induction Profiles and Interferon-Stimulated Genes.
    Zaritsky LA; Bedsaul JR; Zoon KC
    J Virol; 2015 Nov; 89(22):11534-48. PubMed ID: 26355085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Domains of interaction between alpha interferon and its receptor components.
    Uzé G; Di Marco S; Mouchel-Vielh E; Monneron D; Bandu MT; Horisberger MA; Dorques A; Lutfalla G; Mogensen KE
    J Mol Biol; 1994 Oct; 243(2):245-57. PubMed ID: 7932753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mapping human interferon-alpha (IFN-alpha 2) binding determinants of the type I interferon receptor subunit IFNAR-1 with human/bovine IFNAR-1 chimeras.
    Goldman LA; Cutrone EC; Dang A; Hao X; Lim JK; Langer JA
    Biochemistry; 1998 Sep; 37(37):13003-10. PubMed ID: 9737881
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Local type I IFN receptor signaling protects against virus spread within the central nervous system.
    Detje CN; Meyer T; Schmidt H; Kreuz D; Rose JK; Bechmann I; Prinz M; Kalinke U
    J Immunol; 2009 Feb; 182(4):2297-304. PubMed ID: 19201884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human interferons alpha, beta and omega.
    Bekisz J; Schmeisser H; Hernandez J; Goldman ND; Zoon KC
    Growth Factors; 2004 Dec; 22(4):243-51. PubMed ID: 15621727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A structural basis for interferon-alpha-receptor interactions.
    Kumaran J; Wei L; Kotra LP; Fish EN
    FASEB J; 2007 Oct; 21(12):3288-96. PubMed ID: 17517919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Measles virus V protein blocks Jak1-mediated phosphorylation of STAT1 to escape IFN-alpha/beta signaling.
    Caignard G; Guerbois M; Labernardière JL; Jacob Y; Jones LM; ; Wild F; Tangy F; Vidalain PO
    Virology; 2007 Nov; 368(2):351-62. PubMed ID: 17686504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Small Molecule Agonists for the Type I Interferon Receptor: An In Silico Approach.
    Wei L; Bello AM; Majchrzak-Kita B; Salum N; Lewis MM; Kotra LP; Fish EN
    J Interferon Cytokine Res; 2016 Mar; 36(3):180-91. PubMed ID: 26700737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of IFN-alpha/beta signaling by two discrete peptides within measles virus V protein that specifically bind STAT1 and STAT2.
    Caignard G; Bouraï M; Jacob Y; ; Tangy F; Vidalain PO
    Virology; 2009 Jan; 383(1):112-20. PubMed ID: 19007958
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis, photochemical synthesis, DNA binding and antitumor evaluation of novel cyano- and amidino-substituted derivatives of naphtho-furans, naphtho-thiophenes, thieno-benzofurans, benzo-dithiophenes and their acyclic precursors.
    Starcević K; Kralj M; Piantanida I; Suman L; Pavelić K; Karminski-Zamola G
    Eur J Med Chem; 2006 Aug; 41(8):925-39. PubMed ID: 16650510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beta-hairpin peptidomimetics: design, structures and biological activities.
    Robinson JA
    Acc Chem Res; 2008 Oct; 41(10):1278-88. PubMed ID: 18412373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myxoma virus selectively disrupts type I interferon signaling in primary human fibroblasts by blocking the activation of the Janus kinase Tyk2.
    Wang F; Barrett JW; Shao Q; Gao X; Dekaban GA; McFadden G
    Virology; 2009 Apr; 387(1):136-46. PubMed ID: 19254804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis, antitumor evaluation and DNA binding studies of novel amidino-benzimidazolyl substituted derivatives of furyl-phenyl- and thienyl-phenyl-acrylates, naphthofurans and naphthothiophenes.
    Hranjec M; Starcević K; Piantanida I; Kralj M; Marjanović M; Hasani M; Westman G; Karminski-Zamola G
    Eur J Med Chem; 2008 Dec; 43(12):2877-90. PubMed ID: 18395297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ligand binding induces a conformational change in ifnar1 that is propagated to its membrane-proximal domain.
    Strunk JJ; Gregor I; Becker Y; Li Z; Gavutis M; Jaks E; Lamken P; Walz T; Enderlein J; Piehler J
    J Mol Biol; 2008 Mar; 377(3):725-39. PubMed ID: 18294654
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunosuppressive small molecule discovered by structure-based virtual screening for inhibitors of protein-protein interactions.
    Geppert T; Bauer S; Hiss JA; Conrad E; Reutlinger M; Schneider P; Weisel M; Pfeiffer B; Altmann KH; Waibler Z; Schneider G
    Angew Chem Int Ed Engl; 2012 Jan; 51(1):258-61. PubMed ID: 22095772
    [No Abstract]   [Full Text] [Related]  

  • 19. IRF-9/STAT2 [corrected] functional interaction drives retinoic acid-induced gene G expression independently of STAT1.
    Lou YJ; Pan XR; Jia PM; Li D; Xiao S; Zhang ZL; Chen SJ; Chen Z; Tong JH
    Cancer Res; 2009 Apr; 69(8):3673-80. PubMed ID: 19351818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design of chimeric histone deacetylase- and tyrosine kinase-inhibitors: a series of imatinib hybrides as potent inhibitors of wild-type and mutant BCR-ABL, PDGF-Rbeta, and histone deacetylases.
    Mahboobi S; Dove S; Sellmer A; Winkler M; Eichhorn E; Pongratz H; Ciossek T; Baer T; Maier T; Beckers T
    J Med Chem; 2009 Apr; 52(8):2265-79. PubMed ID: 19301902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.